Introduction As one of the most active innovative drug development areas at present, Antibody-Drug Conjugates (ADCs) are rising at an astonishing pace. The global industry interest continues to heat up, with ADC innovative drugs being approved one after another. As of March 2025, a total of 17 ADC products have been approved for market release … Read more
Follow Xiaobai Learning Medicine As of now, 17 ADC drugs have been approved worldwide, of which 5 ADCs are coupled with lysine. Table 1 Summary of ADC Drugs Coupled with Lysine Approved Product Name Company Target DAR Toxin Linker Antibody Type Payload Type Mylotarg Pfizer CD33 2~3 Calicheamicin Hydrazone Link (Acid-labile) IG4 DNA Damaging Agent … Read more
AI Summary The patient had platinum-resistant ovarian cancer with multiple treatment failures, presenting with liver, lymph node, and bone metastases, and conventional treatments were ineffective. After using the novel targeted drug RC88, significant shrinkage of liver metastases and hilar lymph nodes was observed, with a reduction in the extent of bone metastases, achieving partial remission. … Read more
The AACR is always bustling every year, and this year I am particularly focused on the progress of dual payload ADCs. I have written several articles on this topic before, and just a few days ago, I was discussing with my supervisor that “I haven’t seen any dual payload ADCs advancing to clinical trials yet,” … Read more
Written by Wang Cong Edited by Wang Duoyu Formatted by Shui Chengwen Breast cancer has the highest incidence rate among malignant tumors in women, thus it is referred to as the “pink killer.” According to the global cancer burden data released by the International Agency for Research on Cancer (IARC) in 2020, breast cancer has … Read more
GUIDE Editor’s Recommendation Antibody-drug conjugates (ADC) remained popular in 2022. Enhertu redefined the treatment landscape for HER2 breast cancer, making headlines at major academic conferences like ASCO and ESMO; Kelun-Biotech approached a $10 billion license-out deal with multinational pharmaceutical company Merck, setting a new record for local pharmaceutical companies going abroad; the world’s first anti-CD79b … Read more
The Concept and Development History of ADC The treatment of tumors has always undergone a continuous transformation from theory to application, breaking and transforming again. As early as a century ago, scholars proposed the concept of antibody-drug conjugates (ADCs), vividly calling them “magic bullets,” aimed at targeting specific antigens that may exist on the surface … Read more
Introduction Antibody-drug conjugates (ADCs) are “biological bullets” formed by conjugating cytotoxic drugs (payloads) to antibodies via a “linker.” They consist of five components: target, antibody, linker, payload, and conjugation method. Each part is crucial to the function of ADCs, but today we will focus on the linker that connects the antibody and payload, examining the … Read more
Since the first use of cytotoxic chemicals to treat cancer, oncologists have been searching for ways to enhance efficacy without significantly increasing overall toxicity to patients. One of the methods attempted to improve the killing effect on tumor cells is the use of cytotoxic agents with potency at picomolar or lower levels (such as microtubule … Read more
History of ADC Drug Development Phase 1 (1906-1982), the concept of targeted therapy was proposed, and the technology took shape. Phase 2 (1983-2011), transition from clinical trials to commercialization, Mylotarg® was approved for market. Phase 3 (2012-present), explosive growth of ADC products. The five key elements of ADC drugs are target, antibody, linker, cytotoxic agent, … Read more